Krystal Biotech Stock Sees Relative Strength Rating Jump To Noteworthy Territory

When looking for the best stocks to buy and watch, focus on those with rising relative price strength. One stock that fits that bill is Krystal Biotech (KRYS), which had its Relative Strength (RS) Rating upgraded from 79 to 82 Thursday. Is Krystal Biotech stock on your watchlist?


When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.

This unique rating measures technical performance by showing how a stock’s price action over the last 52 weeks measures up against that of other stocks on the major indexes.

Over 100 years of market history reveals that the market’s biggest winners often have an RS Rating of over 80 as they launch their biggest price moves.

Looking For The Best Stocks To Buy And Watch? Start Here

Is Krystal Biotech Stock A Buy?

Krystal Biotech stock is working on a consolidation with an 87.39 entry. See if Krystal Biotech stock can clear the breakout price in volume at least 40% above average.

The Pittsburgh-based biotechnology company showed a 70% earnings contraction last quarter, while sales growth came in flat. Keep an eye out for the company’s next round of numbers on or around May 4.

Krystal Biotech stock earns the No. 132 rank among its peers in the Medical-Biomed/Biotech industry group. Alexion Pharmaceuticals (ALXN) and Halozyme Therapeutics (HALO) are also among the group’s highest-rated stocks.


Find The Best Stocks To Buy Using IBD’s Proprietary Watchlists

MarketSmith’s Tools Can Help The Individual Investor

IBD Live: A New Tool For Daily Stock Market Analysis

Profit From Short-Term Trends With SwingTrader

IBD Stock Rating Upgrades: Rising Relative Strength

Most Related Links :
usnewsmail Governmental News Finance News

Source link

Back to top button